Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of AZD4360 in Advanced Solid Tumours
2024-518281-27-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of AZD4360 in pancreatic adenocarcinoma (PDAC), gastric cancer (GC), esophagogastric junction cancer and 1 more, sponsored by AstraZeneca. Primary endpoints: Frequency of dose-limiting toxicities, Incidence of adverse events and 1 more. Planned start Jan 2026; status: authorised.
02
Drugs
AZD4360
03
Conditions
pancreatic adenocarcinoma (PDAC)gastric cancer (GC)esophagogastric junction cancerbiliary cancer
Beyond the preview
Go deeper on 2024-518281-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518281-27-00.